Nebenwirkungen · Hexyon
Hexyon suspension for injection in pre-filled syringe Hexyon suspension for injection Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed). · Abschnitt 4.8 · PDF-Seite 8
HOS-129752 · Präparat HOS-096795
Hexyon has been administered to 143 preterm infants (born after a gestational period of 24 to 36 weeks) who received a 2-dose primary series at 2 and 4 months of age followed by a booster dose at 11 months of age (concomitantly with other routine infant vaccines). The adverse reactions were similar among all groups of preterm infants, including the extremely preterm infants, and reactions were mainly of mild intensity. No vaccine-related case of apnoea was reported in preterm infants in the clinical trial (See section 4.4 for information on apnoea).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T12:44:00Z · SHA-256 e568d23861dddfe3e060b39a151fc4aa760b88308483c3d532c76ce51a918cf0 · Passage fa184ff7ae46a2bae2f35f87a088d8f9e942476418b3ad4ef676f46d0968ee2f · Zeichen 3270–3825 im Abschnitt